Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Small-cap volatility can threaten predictable retirement income. This note covers swing risk and how to cushion portfolios with prudent diversification.
23,862 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Alibaba leads a broad rally in China’s tech and e-commerce sector as investors brace for quarterly results. Baidu and...
When SpaceX delays its Starship launch, traders take note. But the real question for investors isn’t the setback itse...
Hims & Hers Health announces a major acquisition of Australian digital health firm Eucalyptus, valued at up to $1.15 ...
Novocure faces a pivotal year as TTFields therapy expands and reimbursement pathways evolve. This guide breaks down w...
Bitcoin regained some ground in a choppy session, but analysts say the bounce is more relief than a durable uptrend. ...
Hedge funds linked to Millennium Management are expanding IVV positions as markets wobble, intensifying chatter aroun...
Lucid Group faces a bumpy road as the EV market evolves. This report outlines 2026-2030 price paths for lucid group (...
A fresh rally in semiconductor names has investors buzzing about CPU pricing power and AI infrastructure demand. This...
CareTrust's Q1 2026 earnings reveal steady cash flow and rising occupancy. This article breaks down what the numbers ...
Citi sees the recent aerospace pullback as a rare entry point for Boeing, lifting the target to $260 and signaling a ...
Tech stocks lead gains as the Nasdaq Composite climbs to fresh highs, fueled by AI optimism and strong earnings momen...